CAdVEC

AXP000042.1 · Oncolytic virus

Platform
adenovirus (binary oncolytic adenovirus, helper-dependent)
Originator
Baylor College of Medicine
Sponsor
Baylor College of Medicine

Names

NameTypeSource
CAdVECpreferred name, codecurator, ncit

Virus

Role
Oncolytic
Family
Adenoviridae
Virus
human adenovirus 5 (NCBI Taxonomy 28285)
Strain
binary oncolytic adenovirus (CAdVEC)
Replication
conditionally replicating
Modifications
helper-dependent binary oncolytic adenovirus system
Transgenes
IL12A, IL12B, anti-PD-L1 mini-antibody
Route
intratumoral
Source
evidence

Cross-references

NCI Thesaurus
C158743

Approvals

No regulatory approval recorded.

Clinical trials (1)

TrialTitleStatusPhaseStartPrimary completionEnrolmentConditions
NCT03740256Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid TumorsRecruitingPhase 12020-12-142026-12-3045Bladder Cancer; Breast Cancer; Cancer of the Salivary Gland; Colorectal Cancer; Esophageal Cancer; Gastric Cancer; Head and Neck Squamous Cell Carcinoma; Lung Cancer; Pancreatic Adenocarcinoma; Solid Tumor

Recent changes

No changes recorded in its trials yet.

Clinical papers

No confirmed clinical papers yet.

Other papers

Preclinical studies, reviews and other papers that name it.

PubMedTitleJournalYearLinked by
PMID 38993326Mesenchymal stromal cells protect combined oncolytic and helper-dependent adenoviruses from humoral immunity.Molecular therapy. Methods & clinical development2024name in abstract: CAdVEC
PMID 39653552Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity.Journal for immunotherapy of cancer2024name in abstract: CAdVEC
PMID 36989357Ultralow-dose binary oncolytic/helper-dependent adenovirus promotes antitumor activity in preclinical and clinical studies.Science advances2023name in abstract: CAdVEC

Notes

Oncolytic adenovirus engineered to express IL-12 and an anti-PD-L1 mini-antibody, given intratumorally and followed by autologous HER2-specific CAR T cells (NCT03740256). The CAR T product is a separate program, not entered here.

How to cite

CAdVEC (AXP000042.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000042.html

Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.